S.Korean drugmaker Celltrion gets USFDA approval for allergic asthma biosimilar. Omlyclo approved for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) The drug can also be used to treat immunoglobulin E (IgE)-mediated food allergy and chronic spontaneous urticaria (CSU) The global market for Xolair was estimated to have reached 6 trillion won ($4.1 billion), including 3.7 trillion won in the US, as of 2024. The Korean drugmaker aims to commercialise 22 biosimilar products by 2030, up from the current 11. The drugmaker has obtained approval from the FDA for the US sale of several biosimilars, including Avtozma, an autoimmune disease biosimilar to Actemra, Stoboclo and Osenvelt, biosimilar drugs to Prolia and Xgeva, as well as Covid-19.